Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (5388)	7/25/2001 8:03:44 PM
From: RRICH4	Respond to of 48461

DYNT expanding STS sales to Europe soon Dynatronics Wins ISO 9001/EN 46001 Registration; Completes CE Mark Testing of STS Chronic Pain Devices for European Market SALT LAKE CITY, July 25 /PRNewswire/ -- Dynatronics Corporation (Nasdaq: DYNT - news) today announced that its Salt Lake City facility has received ISO 9001/EN 46001 registration. This expands the facility's existing ISO 9002 quality systems certification to include the design and development of new products. ISO 9001 registration is granted only to organizations that meet stringent quality standards and pass a comprehensive audit of quality systems and design controls. ``The ISO 9001 certification represents an important milestone for Dynatronics' quality systems and processes,'' said Kelvyn H. Cullimore Jr., company president. ``This certification will allow us to begin marketing our new STS chronic pain therapy devices in Europe as soon as the technical file is completed for the CE Mark, which we expect to happen within the next few weeks.'' The CE Mark certification insures full compliance with the European Union Medical Device Directive. The certification process requires a thorough product evaluation and rigorous device testing to assure that the products perform safely and in accordance with specifications. ``Preliminary indications of interest from the European market for our new chronic pain therapy devices have been very good,'' reported Larry K. Beardall, Dynatronics' executive vice president of marketing and sales. ``We believe this new therapy will open the door for our products to the large and growing European market.'' Awareness of Dynatronics' new STS technology continues to increase since its introduction earlier this year. Hundreds of units are currently being used to treat patients across the United States. The company reports that results have continued to affirm the effectiveness of STS treatments in providing symptomatic relief of chronic intractable pain. ``We are seeing a growing number of approvals from insurance companies for patients to receive STS treatments,'' said Beardall. ``As additional research becomes available and the medical community gains experience and confidence with the STS technology, we expect the rate at which insurance companies approve STS treatments to accelerate.'' According to preliminary research studies, over 80 percent of the patients treated with the STS device reported some reduction of pain, while at least one-third of patients treated became totally pain-free. Plans are underway for a multi-center study involving 100 - 200 patients to provide further evidence of the treatment's efficacy. Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, pain management, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. (This press release contains forward-looking statements. Those statements include references to the company's expectations for acceptance of its new technologies and similar statements. The reader is cautioned that actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to changes in the regulatory environment, growth in the physical medicine industry; competitive factors; availability of third-party component parts and products; inventory risks due to shifts in market demand; changes in product mix; and the risk factors listed from time to time in the company's SEC reports, including, but not limited to the report on Form 10-QSB for the quarter and nine months ended March 31, 2001 and Form 10-KSB for the year ended June 30, 2000.) SOURCE: Dynatronics Corporation